Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H28N2O6S2 |
Molecular Weight | 432.555 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O)C(=O)N2CCC[C@H]2C(O)=O
InChI
InChIKey=ZWKRXBCJAUKDCI-MQYQWHSLSA-N
InChI=1S/C18H28N2O6S2/c1-11(15(21)19-7-3-5-13(19)17(23)24)9-27-28-10-12(2)16(22)20-8-4-6-14(20)18(25)26/h11-14H,3-10H2,1-2H3,(H,23,24)(H,25,26)/t11-,12-,13+,14+/m1/s1
Molecular Formula | C18H28N2O6S2 |
Molecular Weight | 432.555 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
230 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL DISULFIDE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
824 μg/L |
100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
878 μg/L |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.31 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6324834/ |
1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
800 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
260 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL DISULFIDE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1197 μg × h/L |
100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1235 μg × h/L |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1150 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6989546/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20.1 μg × h/L/(mg dose) |
2.5 mg single, intravenous dose: 2.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
20.5 μg × h/L/(mg dose) |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
21 μg × h/L/(mg dose) |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6324834/ |
1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.1 h |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.2 h |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CAPTOPRIL blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
69.4% |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAPTOPRIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
750 mg single, oral Overdose |
healthy, 22 n = 1 Health Status: healthy Age Group: 22 Sex: M Population Size: 1 Sources: |
Disc. AE: Hypotension, Loss of consciousness... AEs leading to discontinuation/dose reduction: Hypotension Sources: Loss of consciousness |
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: alprazolam, p.o(10 mg; single) Sources: Page: p.3303 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: F Population Size: 1 Sources: Page: p.3303 |
Disc. AE: Hypotension, Drowsiness... AEs leading to discontinuation/dose reduction: Hypotension Sources: Page: p.3303Drowsiness |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Disc. AE: Cough, Failure heart... AEs leading to discontinuation/dose reduction: Cough (3.8%) Sources: Page: p.750Failure heart (2.4%) Hyperkalaemia (1.6%) Taste perversion Decreased appetite Rash (1%) Hypotension (1.4%) Angio-oedema (0.8%) Arrhythmia (1%) Myocardial infarction (1%) Kidney dysfunction (0.8%) Stroke (0.8%) Angina (0.5%) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: 100S |
unhealthy n = 81 Health Status: unhealthy Condition: Hypertension Sex: M Population Size: 81 Sources: Page: 100S |
Disc. AE: Urticaria, Hypotension... AEs leading to discontinuation/dose reduction: Urticaria (1.2%) Sources: Page: 100SHypotension (2.5%) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | Disc. AE | 750 mg single, oral Overdose |
healthy, 22 n = 1 Health Status: healthy Age Group: 22 Sex: M Population Size: 1 Sources: |
Loss of consciousness | Disc. AE | 750 mg single, oral Overdose |
healthy, 22 n = 1 Health Status: healthy Age Group: 22 Sex: M Population Size: 1 Sources: |
Drowsiness | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: alprazolam, p.o(10 mg; single) Sources: Page: p.3303 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: F Population Size: 1 Sources: Page: p.3303 |
Hypotension | Disc. AE | 500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: alprazolam, p.o(10 mg; single) Sources: Page: p.3303 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: F Population Size: 1 Sources: Page: p.3303 |
Angina | 0.5% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Angio-oedema | 0.8% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Kidney dysfunction | 0.8% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Stroke | 0.8% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Arrhythmia | 1% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Myocardial infarction | 1% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Rash | 1% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Hypotension | 1.4% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Hyperkalaemia | 1.6% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Failure heart | 2.4% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Cough | 3.8% Disc. AE |
50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Decreased appetite | Disc. AE | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Taste perversion | Disc. AE | 50 mg 3 times / day multiple, oral (max) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.750 |
unhealthy, 73 n = 370 Health Status: unhealthy Condition: Hypertension Age Group: 73 Sex: M+F Population Size: 370 Sources: Page: p.750 |
Urticaria | 1.2% Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: 100S |
unhealthy n = 81 Health Status: unhealthy Condition: Hypertension Sex: M Population Size: 81 Sources: Page: 100S |
Hypotension | 2.5% Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: 100S |
unhealthy n = 81 Health Status: unhealthy Condition: Hypertension Sex: M Population Size: 81 Sources: Page: 100S |
Disorder fetal | Disc. AE | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:40:00 GMT 2023
by
admin
on
Sat Dec 16 01:40:00 GMT 2023
|
Record UNII |
Y21D2C2453
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Y21D2C2453
Created by
admin on Sat Dec 16 01:40:00 GMT 2023 , Edited by admin on Sat Dec 16 01:40:00 GMT 2023
|
PRIMARY | |||
|
1091221
Created by
admin on Sat Dec 16 01:40:00 GMT 2023 , Edited by admin on Sat Dec 16 01:40:00 GMT 2023
|
PRIMARY | |||
|
10002934
Created by
admin on Sat Dec 16 01:40:00 GMT 2023 , Edited by admin on Sat Dec 16 01:40:00 GMT 2023
|
PRIMARY | |||
|
DTXSID801024324
Created by
admin on Sat Dec 16 01:40:00 GMT 2023 , Edited by admin on Sat Dec 16 01:40:00 GMT 2023
|
PRIMARY | |||
|
64806-05-9
Created by
admin on Sat Dec 16 01:40:00 GMT 2023 , Edited by admin on Sat Dec 16 01:40:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
IN-VIVO
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |